Sacral Hemangioma Mimicking Bone Metastasis on 18 F-PSMA-1007 PET/CT.
1/5 보강
A 74-year-old man with prostate cancer was referred for an 18 F-PSMA-1007 PET/CT scan for restaging due to a progressive rise in serum prostate-specific antigen levels.
APA
Man X, Dong C, et al. (2025). Sacral Hemangioma Mimicking Bone Metastasis on 18 F-PSMA-1007 PET/CT.. Clinical nuclear medicine, 50(11), 1083-1086. https://doi.org/10.1097/RLU.0000000000005961
MLA
Man X, et al.. "Sacral Hemangioma Mimicking Bone Metastasis on 18 F-PSMA-1007 PET/CT.." Clinical nuclear medicine, vol. 50, no. 11, 2025, pp. 1083-1086.
PMID
40367336 ↗
Abstract 한글 요약
A 74-year-old man with prostate cancer was referred for an 18 F-PSMA-1007 PET/CT scan for restaging due to a progressive rise in serum prostate-specific antigen levels. 18 F-PSMA-1007 PET/CT showed a focal intense activity in the left sacral ala. The sacral lesion corresponded to a hemangioma, which was initially detected on pelvic MRI 6 months ago and remained stable in size. A second 18 F-PSMA-1007 PET/CT performed 8 months after the first PET/CT showed no significant changes in size, density, and activity of the sacral lesion. This case indicates that hemangioma should be included in the differential diagnosis of PSMA-avid sacral lesions.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (3)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.